Towards the development of a longer-acting injectable contraceptive: Past research and current trends

Contraception

Volumn 92, Issue 1, 2015, Pages 3-9

  Halpern, Vera ^a   Stalter, Randy M ^a   Owen, Derek H ^a   Dorflinger, Laneta J ^a   Lendvay, Anja ^a   Rademacher, Kate H ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Drug delivery; Injectable contraceptives; LARCs; Research and development

Indexed keywords

ELCOMETRINE; INJECTABLE CONTRACEPTIVE AGENT; LONG ACTING DRUG; MICROSPHERE; CONTRACEPTIVE AGENT; DELAYED RELEASE FORMULATION; POLYMER;

DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SELF ADMINISTRATION; ENDOMETRIOSIS; FAMILY PLANNING; HORMONAL THERAPY; HUMAN; MEDICAL CARE; MOLECULAR WEIGHT; PARTICLE SIZE; PRODUCT DEVELOPMENT; PROSTATE CANCER; REVIEW; SUSTAINED DRUG RELEASE; CONTRACEPTION; DELAYED RELEASE FORMULATION; FEMALE; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; POLYMERS;

EID: 84932197229     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2015.02.014     Document Type: Review

References (58)

1. B.P. Winner, J.F. Peipert, Q. Zhao, C. Buckel, T. Madden, J.E. Allsworth, and et al. Effectiveness of long-acting reversible contraception N Engl J Med 366 2012 1998 2007
2. J.F. Peipert, T. Madden, J.E. Allsworth, and G.M. Secura Preventing unintended pregnancies by providing no-cost contraception Obstet Gynecol 120 2012 1291 1297
3. P.D. Blumenthal, A. Voedisch, and K. Gemzell-Danielsson Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception Hum Reprod Update 17 2011 121 137
4. D. Hubacher, A. Olawo, C. Manduku, J. Kiarie, and P.L. Chen Preventing unintended pregnancy among young women in Kenya: prospective cohort study to offer contraceptive implants Contraception 86 2012 511 517
5. G. Darmstadt New deal makes Jadelle contraceptive cheaper for countries to purchase Impatient Optimists 2013 Bill & Melinda Gates Foundation
6. K. May, T. Ngo, and D. Hovig Expanding contraceptive choices for women: promising results for the IUD in sub-Saharan Africa 2011 Marie Stopes International London
7. J.E. Darroch, G. Sedgh, and H. Ball Contraceptive technologies: responding to women's needs 2011 Guttmacher Institute New York
8. United Nations Department of Economic and Social Affairs, Population Division World Contraceptive Use 2011
9. J. Stanback, J. Spieler, I. Shah, and W.R. Finger Community-based health workers can safely and effectively administer injectable contraceptives: conclusions from a technical consultation Contraception 81 2010 181 184
10. F. Lakha, C. Henderson, and A. Glasier The acceptability of self-administration of subcutaneous Depo-Provera Contraception 72 2005 14 18
11. J.N. Baumgartner, C. Morroni, R.D. Mlobeli, and et al. Timeliness of contraceptive reinjections in South Africa and its relation to unintentional discontinuation Int Fam Plan Perspect 33 2007 66 74
12. J.K. Ruminjo, C.B. Sekadde-Kigondu, J.G. Karanja, R. Rivera, M. Nasution, and T. Nutley Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya Contraception 72 2005 138 145
13. W.M. Castle, K.E. Sapire, and K.A. Howard Efficacy and acceptability of injectable medroxyprogesterone. A comparison of 3-monthly and 6-monthly regimens S Afr Med J 53 1978 842 845
14. Z. Abouelfadel, and E.D. Crawford Leuprorelin depot injection: patient considerations in the management of prostatic cancer Ther Clin Risk Manag 4 2008 513 526
15. G. Benagiano, C. d'Arcangues, J. Harris Requejo, A. Schafer, L. Say, and M. Merialdi The special programme of research in human reproduction: forty years of activities to achieve reproductive health for all Gynecol Obstet Invest 74 2012 190 217
16. G. Benagiano, and M. Merialdi Carl Djerassi and the World Health Organisation special programme of research in human reproduction J Reprod Med Endokrinol 8 2011
17. E.B. McDaniel, and T. Pardthaisong Use-effectiveness of six-month injections of DMPA as a contraceptive Am J Obstet Gynecol 119 1974 175 180
18. E.V. Mackay, S.K. Khoo, and R.R. Adam Contraception with a six-monthly injection of progestogen. 2. Effects on cervical mucus secretion and endocrine function Aust N Z J Obstet Gynaecol 11 1971 156 163
19. P.C. Schwallie, and J.R. Assenzo Contraceptive use - efficacy study utilizing Depo-Provera administered as an injection once every six months Contraception 6 1972 315 327
20. J. Jain, C. Dutton, A. Nicosia, C. Wajszczuk, F.R. Bode, and D.R. Mishell Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera Contraception 70 2004 11 18
21. H. Toguchi Formulation study of leuprorelin acetate to improve clinical performance Clin Ther 14 Suppl. A 1992 121 130
22. S. Freiberg, and X.X. Zhu Polymer microspheres for controlled drug release Int J Pharm 282 2004 1 18
23. B. Lu, Z.R. Wang, and H. Yang Long-acting delivery microspheres of levo-norgestrel-poly(3-hydroxybutyrate): their preparation, characterization and contraceptive tests on mice J Microencapsul 18 2001 55 64
24. M.D. Dhanaraju, D. Gopinath, M.R. Ahmed, R. Jayakumar, and C. Vamsadhara Characterization of polymeric poly(epsilon-caprolactone) injectable implant delivery system for the controlled delivery of contraceptive steroids J Biomed Mater Res A 76 2006 63 72
25. M. Dasaratha Dhanaraju, K. Vema, R. Jayakumar, and C. Vamsadhara Preparation and characterization of injectable microspheres of contraceptive hormones Int J Pharm 268 2003 23 29
26. L.R. Beck, V.Z. Pope, T.R. Tice, and R.M. Gilley Long-acting injectable microsphere formulation for the parenteral administration of levonorgestrel Adv Contracept 1 1985 119 129
27. S.H. Wang, L.C. Zhang, F. Lin, and et al. Controlled release of levonorgestrel from biodegradable poly(d,l-lactide-co-glycolide) microspheres: in vitro and in vivo studies Int J Pharm 301 2005 217 225
28. M.D. Dhanaraju, R. Rajkannan, D. Selvaraj, R. Jayakumar, and C. Vamsadhara Biodegradation and biocompatibility of contraceptive-steroid-loaded poly(dl-lactide-co-glycolide) injectable microspheres: in vitro and in vivo study Contraception 74 2006 148 156
29. Y. Sun, J. Wang, X. Zhang, and et al. Synchronic release of two hormonal contraceptives for about one month from the PLGA microspheres: in vitro and in vivo studies J Control Release 129 2008 192 199
30. S.R. Machado, L.O. Lunardi, A.P. Tristao, and J.M. Marchetti Preparation and characterization of d,l-PLA loaded 17-beta-Estradiol valerate by emulsion/evaporation methods J Microencapsul 26 2009 202 213
31. S. Puthli, and P. Vavia Formulation and performance characterization of radio-sterilized "progestin-only" microparticles intended for contraception AAPS PharmSciTech 10 2009 443 452
32. D. Trantolo, Y.-Y. Hsu, J. Gresser, D. Wise, and A. Moo-Young Biodegradable systems for long-acting nesterone D. Wise, Handbook of pharmaceutical controlled release technology 2000 Marcel Dekker, Inc. New York
33. L.R. Beck, V.Z. Pope, C.E. Flowers, and et al. Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive Biol Reprod 28 1983 186 195
34. R. Rivera, G. Alvarado, C. Flores, S. Aldaba, and A. Hernandez Norethisterone contraceptive microspheres J Steroid Biochem 27 1987 1003 1007
35. G.S. Grubb, J.D. Welch, L. Cole, A. Goldsmith, and R. Rivera A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study Fertil Steril 51 1989 803 810
36. M. Singh, B.B. Saxena, R. Singh, J. Kaplan, and W.J. Ledger Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres (NET-90): phase III clinical study Adv Contracept 13 1997 1 11
37. Y. Shi, and L.C. Li Current advances in sustained-release systems for parenteral drug delivery Expert Opin Drug Deliv 2 2005 1039 1058
38. C.B. Packhaeuser, J. Schnieders, C.G. Oster, and T. Kissel In situ forming parenteral drug delivery systems: an overview Eur J Pharm Biopharm 58 2004 445 455
39. Z.H. Gao, W.R. Crowley, A.J. Shukla, J.R. Johnson, and J.F. Reger Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in vivo evaluation Pharm Res 12 1995 864 868
40. Z.H. Gao, A.J. Shukla, J.R. Johnson, and W.R. Crowley Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: in vitro evaluation Pharm Res 12 1995 857 863
41. C.J. Wheaton, A. Savage, A. Shukla, and et al. The use of long acting subcutaneous levonorgestrel (LNG) gel depot as an effective contraceptive option for cotton-top tamarins (Saguinus oedipus) Zoo Biol 30 2011 498 522
42. J. Parker The London Summit and beyond The Economist 2012
43. E.G. Sutherland, C. Otterness, and B. Janowitz What happens to contraceptive use after injectables are introduced? An analysis of 13 countries Int Perspect Sex Reprod Health 37 2011 202 208
44. N. Kumar, R.S. Langer, and A.J. Domb Polyanhydrides: an overview Adv Drug Deliv Rev 54 2002 889 910
45. J.M. Buriak Organometallic chemistry on silicon and germanium surfaces Chem Rev 102 2002 1271 1308
46. L. Cheng, E. Anglin, F. Cunin, and et al. Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle Br J Ophthalmol 92 2008 705 711
47. Q. Xu, M. Hashimoto, T.T. Dang, and et al. Preparation of monodisperse biodegradable polymer microparticles using a microfluidic flow-focusing device for controlled drug delivery Small 5 2009 1575 1581
48. Q. Shang, X. Wang, M. Apley, S.B. Kukanich, and C. Berkland PPF microsphere depot sustains NSAID blood levels with infusion-like kinetics without "burst" J Vet Pharmacol Ther 35 2012 231 238
49. C. Berkland, K. Kim, and D.W. Pack PLG microsphere size controls drug release rate through several competing factors Pharm Res 20 2003 1055 1062
50. T.E. Canto De Cetina, P. Canto, and M. Ordonez Luna Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate Contraception 63 2001 143 146
51. Z.W. Lei, S.C. Wu, R.J. Garceau, and et al. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception Contraception 53 1996 357 361
52. E.G. Raymond, M. Singh, D.F. Archer, B.B. Saxena, J. Baker, and D. Cole Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants Fertil Steril 66 1996 954 961
53. L.J. Dorflinger Metabolic effects of implantable steroid contraceptives for women Contraception 65 2002 47 62
54. A.E. Schindler, C. Campagnoli, R. Druckmann, and et al. Classification and pharmacology of progestins Maturitas 61 2008 171 180
55. N. Kumar, S.S. Koide, Y. Tsong, and K. Sundaram Nestorone: a progestin with a unique pharmacological profile Steroids 65 2000 629 636
56. R. Sitruk-Ware, and A. Nath The use of newer progestins for contraception Contraception 82 2010 410 417
57. V. Brache, L.J. Payan, and A. Faundes Current status of contraceptive vaginal rings Contraception 87 2013 264 272
58. C.S. Morrison, P.L. Chen, C. Kwok, and et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis PLoS Med 12 2015 e1001778